As of close of business last night, Aadi Bioscience Inc’s stock clocked out at $1.94, down -9.77% from its previous closing price of $2.15. In other words, the price has decreased by -$0.2100 from its previous closing price. On the day, 546910 shares were traded.
Ratios:
To gain a deeper understanding of AADI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.30 and its Current Ratio is at 6.48. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.01.
On January 11, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Desai Neil sold 14,964 shares for $2.10 per share. The transaction valued at 31,415 led to the insider holds 1,411,543 shares of the business.
Desai Neil sold 27,036 shares of AADI for $53,226 on Mar 01 ’24. The EXECUTIVE CHAIRMAN now owns 1,426,507 shares after completing the transaction at $1.97 per share. On Feb 01 ’24, another insider, Desai Neil, who serves as the Executive Chairman of the company, sold 42,000 shares for $1.74 each. As a result, the insider received 73,269 and left with 1,453,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AADI now has a Market Capitalization of 47.58M and an Enterprise Value of -70.39M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.05 while its Price-to-Book (P/B) ratio in mrq is 0.40. Its current Enterprise Value per Revenue stands at -3.03 whereas that against EBITDA is 1.12.
Stock Price History:
Over the past 52 weeks, AADI has reached a high of $8.86, while it has fallen to a 52-week low of $1.55. The 50-Day Moving Average of the stock is 1.8673, while the 200-Day Moving Average is calculated to be 4.5860.
Shares Statistics:
It appears that AADI traded 601.12K shares on average per day over the past three months and 990.82k shares per day over the past ten days. A total of 24.44M shares are outstanding, with a floating share count of 17.37M. Insiders hold about 29.19% of the company’s shares, while institutions hold 41.29% stake in the company. Shares short for AADI as of Feb 29, 2024 were 949.34k with a Short Ratio of 1.58, compared to 1.14M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.87% and a Short% of Float of 5.89%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.65 for the current quarter, with a high estimate of -$0.58 and a low estimate of -$0.73, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.65 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$2.36 and -$2.56 for the fiscal current year, implying an average EPS of -$2.49. EPS for the following year is -$2.67, with 4 analysts recommending between -$2.18 and -$2.97.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $6.29M. It ranges from a high estimate of $6.59M to a low estimate of $5.87M. As of the current estimate, Aadi Bioscience Inc’s year-ago sales were $5.28M, an estimated increase of 19.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $6.57M, an increase of 12.00% less than the figure of $19.20% in the same quarter last year. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.05M.
A total of 5 analysts have provided revenue estimates for AADI’s current fiscal year. The highest revenue estimate was $24.62M, while the lowest revenue estimate was $23.3M, resulting in an average revenue estimate of $24.13M. In the same quarter a year ago, actual revenue was $15.22M, up 58.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $27.22M in the next fiscal year. The high estimate is $28.95M and the low estimate is $25M. The average revenue growth estimate for next year is up 12.80% from the average revenue estimate for this year.
